Understanding the current state of peptide research helps contextualize these decisions within the broader scientific landscape
This is when you might notice yourself pushing food away halfway through dinner or forgetting to snack in the afternoonchanges that feel effortless rather than forced
GH secretagogue comparison Property Class CJC-1295 No DAC GHRH analog CJC-1295 with DAC GHRH analog (binds albumin) Sermorelin GHRH analog Ipamorelin GHRP (ghrelin mimetic) Property Half-life CJC-1295 No DAC ~30 minutes CJC-1295 with DAC 68 days Sermorelin 1020 minutes Ipamorelin ~2 hours Property Dosing frequency CJC-1295 No DAC 13x daily CJC-1295 with DAC 12x weekly Sermorelin 12x daily Ipamorelin 13x daily Property Common dose range CJC-1295 No DAC 100300 mcg per injection CJC-1295 with DAC 1,0002,000 mcg per week Sermorelin 100500 mcg per injection Ipamorelin 100300 mcg per injection Property GH release shape CJC-1295 No DAC Pulsatile, physiological CJC-1295 with DAC Sustained elevation Sermorelin Pulsatile Ipamorelin Brief, selective pulse Property FDA status CJC-1295 No DAC Not approved CJC-1295 with DAC Not approved Sermorelin Previously approved
This imbalance leads to impaired cognitive and motor functions, including confusion, memory loss, and decreased coordination
Other GLP-1 Medications: Liraglutide, Dulaglutide, and Exenatide Beyond semaglutide and tirzepatide, the GLP-1 drug class includes several other options with different pharmacokinetic profiles and dosing schedules
The 2026 Regulatory Landscape The legal ground beneath compounded GLP-1 medications shifted significantly in late 2025 and early 2026
